TK 210 ELISA
Cancer Therapy Monitoring (e.g., Breast Cancer)
Commercial / Clinical DevelopmentActive
Key Facts
Indication
Cancer Therapy Monitoring (e.g., Breast Cancer)
Phase
Commercial / Clinical Development
Status
Active
Company
About IDL Diagnostics
IDL Diagnostics, formerly known as AroCell, is a commercial-stage diagnostics company specializing in cancer monitoring. Its core technology is based on the Thymidine Kinase 1 (TK1) biomarker, offered in formats like the UBC Rapid point-of-care test and the TK 210 ELISA for automated platforms. The company is actively commercializing its products through distributor partnerships in Asia and Europe while engaging in clinical studies to expand the utility of its TK1 assays across various cancer types.
View full company profile